

## Sphere Medical Holding Limited

### Tony Martin Appointed as Chairman

Sphere Medical Holding Limited ('Sphere Medical' or 'Sphere'), the Cambridge (UK) based medical microsystems company, is pleased to announce that Dr. Tony Martin has joined the Board as Non-Executive Chairman.

Dr. Martin is an entrepreneurial executive with a long history of creating substantial value in the life sciences arena. Dr. Martin is also the Non-Executive Chairman of NeuTec Pharma, Chairman of Wound Solutions Ltd., and a director of Protodyne, a US based life sciences company. Until recently, he served as President and CEO of Molecular Probes Inc., which was sold for \$325 million in a transaction he initiated. Previously, he was President of Molecular Biology for Invitrogen Corporation and before that he was President and Chief Executive Officer of Invitrogen B.V. in Holland. Between 1995 and 2000, he was Chairman and CEO of AZUR Environmental Inc, a US company involved in environmental testing. Before this, he was Chief Executive of Celsis International plc, where he successfully floated the company on the London Stock Exchange. He was also Chairman of Tepnel Life Sciences plc.

**Dr. Stuart Hendry, CEO of Sphere Medical, said:** "I am delighted that someone of Tony's strength and experience has agreed to help steer Sphere through its next exciting and demanding phase of growth and prepare the Company for a listing in 2006. In addition, I would like to personally thank Richard Lyman of Oakes Lyman & Co. Ltd. for his work as Chairman through the Sphere's recent successes and I am pleased that he will remain contributing to Sphere as a Non-Executive Director."

**Dr. Tony Martin, Non-Executive Chairman of Sphere Medical, said:** "Sphere's technology has the potential to revolutionise treatment for critically ill patients and offers a broad platform for many point of care tests, which should fundamentally change the practice of monitoring key clinical parameters in a critical care setting. I am very pleased to be joining the Board at this formative stage of the Company's development and look forward to helping build Sphere into a major provider of innovative products for improving the quality of healthcare throughout the world."

#### For more information contact:

Dr. Stuart Hendry, Chief Executive Officer +44 (0)1223 875222  
[www.spheremedical.com](http://www.spheremedical.com)

Tim Anderson, Mary-Jane Johnson, Isabel Podda +44 (0)20 7466 5000  
Buchanan Communications

#### Notes for editors:

Sphere Medical Limited, founded in 2002 and based in Cambridge (UK), is a medical microanalyser company with leading edge microchip technology that was originally developed by Siemens. The technology, which Sphere will develop and manufacture, allows minimally invasive, real time measurement of critical patient parameters leading to improved patient care, safety and reduced duration of hospital stay and costs representing the future of intensive care medicine. Other advantages of the technology include ease of use, lower risk of infection, blood conservation and compatibility with current hospital systems. The company, which is expanding rapidly, recently relocated to new headquarters on the Harston Mill Campus, Cambridge. Sphere has a considerable patent estate including internally

developed and in-licensed intellectual property, and includes 16 patent families that have been transferred from Siemens. In March 2005 Sphere announced that it had closed a £4 million private equity funding round which was significantly oversubscribed. The money raised will be used to continue the development of Sphere's microchip-based medical products. For more information please see [www.spheremedical.com](http://www.spheremedical.com)